You are here: Industry Insights > multiple sclerosis

News List

Blocking brain inflammation in multiple sclerosis with gut immune cells fiercebiotech
January 07, 2019
While some immune cells cause the damaging brain inflammation of multiple sclerosis, others work to mitigate it. Researchers at the University of Toronto and the University of California.....
Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis drugs
December 26, 2018
Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced that Alkermes has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ....
FDA hits Sanofi's struggling Lemtrada with new safety warning over reports of stroke, artery tears fiercepharma
December 05, 2018
Sanofi’s Lemtrada is already struggling in a tough multiple sclerosis field, and a new FDA safety warning isn’t going to help matters.
Up to 10-years of follow-up data reaffirm safety profile of Mavenclad (cladribine tablets) worldpharmanews
October 12, 2018
Merck, the vibrant science and technology company, today announced the presentation of new data for MAVENCLAD® (cladribine tablets) at the 34th Congress of the European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS) in Berlin, German
Multiple sclerosis drug slows brain shrinkage europeanpharmaceuticalreview
September 04, 2018
In a recent clinical study, ibudilast slowed brain shrinkage better than a placebo in the brains of patients with multiple sclerosis…
Ex-Biogen manager claims she was fired after filing integrity complaint fiercepharma
July 31, 2018
Biogen didn't have much success on the market with multiple sclerosis med Zinbryta, and now the drug is at the center of a discrimination and retaliation lawsuit by a former manager.
Roche's multiple sclerosis drug Ocrevus lowered patients' vaccine responses: study fiercepharma
June 07, 2018
Roche’s multiple sclerosis newcomer Ocrevus was approved by the FDA last March bearing a warning about immunization.
Sanofi Genzyme partners with MSSI to support multiple sclerosis community financialexpress
June 01, 2018
Sanofi Genzyme, the specialty care global business unit of Sanofi, and Multiple Sclerosis Society of India (MSSI) join hands to raise awareness and to provide better treatment solutions for the 130,000 people living with multiple sclerosis (MS) in India.
First clues to the causes of multiple sclerosis worldpharmanews
May 23, 2018
Multiple sclerosis, which affects 1 in 1,000 people, is frequently characterised by relapses associated with variable functional impairments including among others vision problems, impairment of locomotor functions or difficulties with speech.
First clues to the causes of multiple sclerosis worldpharmanews
May 23, 2018
Multiple sclerosis, which affects 1 in 1,000 people, is frequently characterised by relapses associated with variable functional impairments including among others vision problems, impairment of locomotor functions or difficulties with speech.

Previous page 1 2 3 4 5 6 Next page